DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Analysis By Drug Class And Segment Forecasts, 2014 - 2025" report to their offering.
The global HIV-1 therapeutics market is expected to reach a value of USD 15.8 billion by 2025, growing at a CAGR of 1.4%. According to the report, HIV continues to be one of the most challenging public health issues worldwide.
The key factors responsible for driving the market growth include the increasing incidence of HIV infections especially amongst the youth due to unprotected sexual practices, exposure to needles or syringes contaminated with infected body fluids or tissues, lack of awareness regarding transmission risk factors, etc. The estimated number of people suffering from HIV in 2015 was recorded to be more than 35 million according to AVERT, a UK-based HIV and AIDS charity.
HIV has vastly affected people from developing and under developed countries, mainly the Asian and African regions. As this infection is not curable at present, the primary aim of antiretroviral therapy is to suppress viral replication in patients usinganti-retroviral agents that are grouped into six different drug classes based on their mechanism of action.
The combination therapy entails medicines from at least two to three drug classes as each class targets different steps in the HIV lifecycle. The combination of drugs is chosen based on patients' medical history, predisposition to adverse effects of antiretroviral drugs, co-infections with other diseases, and others.
Key Topics Covered:
1 Methodology & Scope
2 Executive Summary and Market Snapshot
3 HIV-1 Therapeutics Market Variables, Trends& Scope
4 HIV-1 TherapeuticsMarket Drug Class Estimates & Trend Analysis
5 HIV-1 Therapeutics Market Regional Estimates & Trend Analysis
6 Competitive Landscape
For more information about this report visit http://www.researchandmarkets.com/research/fcwvqt/human